Patents Assigned to Myokardia, Inc.
  • Pyrazole compounds and preparation thereof
    Patent number: 11873289
    Abstract: The present invention provides processes for preparation of substituted pyrazole compounds of formula II, that can be used as intermediates for preparation of substituted piperidine urea compounds useful for the treatment of dilated cardiomyopathy (DCM). R2 is independently selected from F, C1-C4 alkyl, C1-C4 haloalkyl, R3 is independently selected from H, F, C1-C4 alkyl, C1-C4 haloalkyl, R4 is C1-C4 alkyl, R6 is H or a protecting group and R7 is selected from H, CI or trialkylsilyl.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: January 16, 2024
    Assignee: MyoKardia, Inc.
    Inventors: Sunil Sharma, Dinesh Jangid, Priyanka Dhaka, Siddharth Madhwal, Bharat Kumar, Kapil Kumar, Rajdeep Anand, Anurag Jain
  • TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE
    Publication number: 20220265629
    Abstract: Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.
    Type: Application
    Filed: May 18, 2020
    Publication date: August 25, 2022
    Applicant: MyoKardia, Inc.
    Inventors: Jean-Francois Tamby, Chun Yang, Timothy Carlson
  • 4-methylsulfonyl-substituted piperidine urea compounds
    Patent number: 11123337
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: September 21, 2021
    Assignee: MyoKardia, Inc.
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
    Patent number: 11034693
    Abstract: The present disclosure provides novel 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones of formula (I): The compounds of formula (I) are useful for the treatment of hypertrophic cardiomyopathy (HCM), conditions associated with left ventricular hypertrophy, conditions associated with diastolic dysfunction, and/or symptoms associated thereof. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: June 15, 2021
    Assignee: MyoKardia, Inc.
    Inventors: Mark Grillo, Brian Kane, Johan Oslob, Min Zhong, Fabienne Thompson
  • 4-methylsulfonyl-substituted piperidine urea compounds
    Patent number: 10758525
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: September 1, 2020
    Assignee: MyoKardia, Inc.
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • 4-methylsulfonyl-substituted piperidine urea compounds
    Patent number: 9925177
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: March 27, 2018
    Assignee: MyoKardia, Inc.
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Bicyclic-pyrimidinedione compounds
    Patent number: 9663516
    Abstract: The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 30, 2017
    Assignee: MYOKARDIA, INC.
    Inventors: Johan Oslob, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Mark Grillo, Brian Kane, Robert McDowell, Yonghong Song, Min Zhong
  • Pyrimidinedione compounds
    Patent number: 9585883
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 7, 2017
    Assignee: MYOKARDIA, INC.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Cycloalkyl-substituted pyrimidinedione compounds
    Patent number: 9199945
    Abstract: The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 1, 2015
    Assignee: Myokardia, Inc.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran, Pu-Ping Lu
  • Pyrimidinedione compounds
    Patent number: 9181200
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 10, 2015
    Assignee: Myokardia, Inc.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran